PMID- 18339472
OWN - NLM
STAT- MEDLINE
DCOM- 20090323
LR  - 20151119
IS  - 0302-2838 (Print)
IS  - 0302-2838 (Linking)
VI  - 54
IP  - 6
DP  - 2008 Dec
TI  - Preoperative serum sex hormone-binding globulin as a predictive marker for 
      extraprostatic extension of tumor in patients with clinically localized prostate 
      cancer.
PG  - 1324-32
LID - 10.1016/j.eururo.2008.02.032 [doi]
AB  - OBJECTIVES: We investigated the relationships of serum sex hormone-binding 
      globulin (SHBG) level with known prognostic factors for prostate cancer in men 
      who received radical retropubic prostatectomy (RRP) for clinically localized 
      prostate cancer. METHODS: Preoperative serum levels of SHBG were analyzed in 288 
      consecutive patients who were scheduled to undergo RRP for clinically localized 
      prostate cancer. We investigated the potential associations of preoperative serum 
      SHBG level with various clinical and pathological factors. Accuracy of variables 
      in predicting adverse pathological features was assessed via receiver operator 
      characteristics (ROC) curves. RESULTS: In univariate analysis, preoperative serum 
      SHBG level was observed to be significantly associated with extraprostatic 
      extension of a tumor (p=0.019) and with pathological Gleason score (p=0.001). In 
      multivariate analysis, serum SHBG level (p=0.039) along with serum PSA (p<0.001) 
      level, biopsy Gleason score (p<0.001), and clinical stage (p=0.004) was observed 
      to be an independent predictor of the extraprostatic extension of prostate 
      cancer. The area under ROC curve that demonstrated the performance of a 
      multivariate logistic regression model (MLRM), which included serum SHBG level 
      and other preoperative variables, in predicting extraprostatic extension of tumor 
      was larger than that of MLRM without SHBG (0.797 vs. 0.758, p=0.121). Meanwhile, 
      serum SHBG level was not observed to be significantly associated with 
      pathological Gleason score in multivariate analysis (p=0.303). CONCLUSIONS: Our 
      data showed that serum SHBG level is an independent predictive factor for 
      extraprostatic extension of tumor in patients with clinically localized prostate 
      cancer.
FAU - Lee, Sang Eun
AU  - Lee SE
AD  - Department of Urology, Seoul National University Bundang Hospital, Seongnam, 
      Korea.
FAU - Chung, Jae Seung
AU  - Chung JS
FAU - Han, Byung Kyu
AU  - Han BK
FAU - Park, Chan Soo
AU  - Park CS
FAU - Moon, Ki Hyuk
AU  - Moon KH
FAU - Byun, Seok-Soo
AU  - Byun SS
FAU - Choe, Gheeyoung
AU  - Choe G
FAU - Hong, Sung Kyu
AU  - Hong SK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080307
PL  - Switzerland
TA  - Eur Urol
JT  - European urology
JID - 7512719
RN  - 0 (Androgens)
RN  - 0 (Biomarkers)
RN  - 0 (Sex Hormone-Binding Globulin)
SB  - IM
CIN - Eur Urol. 2008 Dec;54(6):1331-2. PMID: 18339473
MH  - Aged
MH  - Androgens/physiology
MH  - Biomarkers/blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Predictive Value of Tests
MH  - Preoperative Care
MH  - Prostatic Neoplasms/*blood/*pathology
MH  - Sex Hormone-Binding Globulin/*analysis
EDAT- 2008/03/15 09:00
MHDA- 2009/03/24 09:00
CRDT- 2008/03/15 09:00
PHST- 2007/09/16 00:00 [received]
PHST- 2008/02/28 00:00 [accepted]
PHST- 2008/03/15 09:00 [pubmed]
PHST- 2009/03/24 09:00 [medline]
PHST- 2008/03/15 09:00 [entrez]
AID - S0302-2838(08)00264-9 [pii]
AID - 10.1016/j.eururo.2008.02.032 [doi]
PST - ppublish
SO  - Eur Urol. 2008 Dec;54(6):1324-32. doi: 10.1016/j.eururo.2008.02.032. Epub 2008 
      Mar 7.